DBV Technologies S.A. (NASDAQ:DBVT) on Tuesday released data from the VITESSE Phase 3 study assessing the safety and efficacy of VIASKIN Peanut patch for peanut-allergic children aged 4 to 7 years.DBV Technologies stock is challenging resistance. What’s driving DBVT to record levels?Trial DataThe pivotal trial met its primary endpoint.VIASKIN Peanut demonstrated a statistically significant treatment effect, with 46.6% of children in the VIASKIN Peanut arm meeting the treatment responder criteria after 12 mo ...